Alla studier
Aktiv men inte rekryterandeFAS1, FAS2INTERVENTIONELL

A Phase I/II Study of VTX-801 in Adult Patients With Wilson's Disease

This research study is looking at a new treatment called VTX-801 for adults with Wilson's Disease. VTX-801 is a type of gene therapy, which means it aims to address the root cause of the disease. The study will last up to five years and involves giving the treatment directly into a vein. Researchers will carefully check the safety of VTX-801, how well people tolerate it, and what effects it has on the body. A key part of the study is seeing if patients can gradually reduce their usual Wilson's Disease medications after receiving VTX-801. This is a "Phase I/II" study, meaning it's an early step to understand the treatment better in a small group of people.

Överblick

Status
Aktiv men inte rekryterande
Fas
FAS1, FAS2
Sponsor
Vivet Therapeutics SAS
Inskrivningsmål
4
Starta
03 Sep 2021
Beräknad slutförande
18 Jun 2029

Resultat

Resultat från denna studie

Publicerad Januari 2026

Resultaten har publicerats för denna studie.

Primärt resultat
Safety and Tolerability Profile (Including Treatment-emergent Adverse Events (TEAE)) - Number of Participants
AEs will be summarized based on the date of onset for the event. Number of treatment-emergent AEs will be provided by SOC and PT, by dose cohort and overall.
Fullständiga resultat i registret

Vad handlar denna studie om?

Wilson's Disease is a rare genetic condition where too much copper builds up in the body, primarily in the liver and brain. If left untreated, this can cause serious health problems. Current treatments focus on removing excess copper and preventing its build-up, and people usually need to take medication for life.

This study, called a "Phase I/II" study, is investigating a new treatment called VTX-801. VTX-801 is a "gene therapy," which is a type of medicine that tries to correct the problem by introducing a healthy copy of the gene that is faulty in people with Wilson's Disease. The aim is to help the body process copper properly again. This means it could potentially be a long-lasting treatment.

The main goals of this study are to find out if VTX-801 is safe for adults with Wilson's Disease and how well their bodies handle it. Researchers also want to see what effects the treatment has on the body and whether patients might eventually be able to reduce or even stop their regular Wilson's Disease medication. The study will follow participants for up to five years to carefully observe these long-term effects.

Viktiga punkter

  • Tests a new gene therapy (VTX-801) for Wilson's Disease.
  • Aims to check safety, tolerability, and effectiveness.
  • Could potentially reduce the need for current medications.
  • Involves treatments given into a vein.
  • Requires commitment for up to five years of monitoring.
  • Only for adults aged 18-65 with stable Wilson's Disease.

Vem kan vara berättigad?

To join this study, you would need to be an adult between 18 and 65 years old with an official diagnosis of Wilson's Disease. You should also be currently receiving treatment for your Wilson's Disease according to standard medical advice and your condition needs to have been stable for at least one year. This means your symptoms haven't changed much, and tests that check copper levels are steady.

There are also some reasons why you might not be able to join. For example, if you have certain liver problems, such as signs of serious liver damage or abnormal results in some blood tests (like those for liver function or blood clotting), you wouldn't be eligible. The study also cannot include individuals with significant kidney problems, or certain infections like HIV or hepatitis. People with a history of diabetes or high body mass index (BMI) over 35 kg/m2 would also be unable to participate.

If you are pregnant or breastfeeding, or if you have any other serious health conditions or medications that might interfere with the study, you would not be able to take part. The research team will carefully review all your medical information to make sure joining the study is safe for you.

Kan denna studie passa dig?

Svara på dessa snabba frågor för att se om du kan vara berättigad. Detta är endast en vägledning — forskarteamet fattar det slutgiltiga beslutet.

  1. Är du mellan 18 och 65 år gammal?
  2. Have you been officially diagnosed with Wilson's Disease?
  3. Have you been receiving standard treatment for your Wilson's Disease, and has your condition been stable for at least one year?
  4. Do you have good overall liver and kidney function according to your doctor?
  5. Are you free from certain infections like HIV or hepatitis?
  6. Är du inte gravid eller ammar?
Svara på varje fråga för att se ditt resultat.

Vad innebär deltagande?

If you join this study, you would receive the study medicine, VTX-801, which is given through a drip into your vein (intravenous infusion). The study plans to test different doses of VTX-801. After receiving the treatment, researchers will closely monitor you to see how your body reacts and if your current Wilson's Disease treatment can be gradually reduced or even stopped.

Your participation would involve regular visits to the study clinic for up to five years. During these visits, the research team would conduct various assessments. These might include physical examinations, blood and urine tests, and other procedures to check your health, how well the treatment is working, and to monitor for any side effects. These assessments help the doctors understand the safety and effects of VTX-801 over time. The exact number and frequency of visits would be detailed by the study team.

Potentiella risker och fördelar

Participating in a clinical trial like this could potentially offer benefits, such as access to a new treatment that might improve your condition or reduce your need for lifelong medication. However, as VTX-801 is an experimental treatment, there are also potential risks involved, and side effects are possible, some of which might not yet be known. The research team will explain all known risks to you. You have the right to withdraw from the study at any time, for any reason, without it affecting your usual medical care.

Platser (10)

  • UC Davis medicinska centrum
    Verifierat postnummer
    Sacramento, USA
  • Yale University School of Medecine
    Verifierat postnummer
    New Haven, USA
  • Advent Hälsa
    Verifierat postnummer
    Orlando, USA
  • University of Michigan Health System
    Verifierat postnummer
    Ann Arbor, USA
  • Wake Forest School of Medicine
    Verifierat postnummer
    Winston-Salem, USA
  • University of Texas Southwestern Medical Center
    Verifierat postnummer
    Dallas, USA
  • Aarhus Universitetssjukhus
    Verifierat postnummer
    Aarhus, Danmark
  • Universitetssjukhuset Essen
    Verifierat postnummer
    Essen, Tyskland
  • Universitätsklinikum Tübingen (UKT)
    Verifierat postnummer
    Tübingen, Tyskland
  • Royal Surrey County Hospital
    Verifierat postnummer
    Guildford, United Kingdom

Vanliga frågor

What is Wilson's Disease?

Wilson's Disease is a genetic condition where your body collects too much copper, which can harm organs like your liver and brain.

What is a 'gene therapy'?

Gene therapy is a new type of treatment that tries to fix the root cause of a disease by adding or changing genes in your body.

What does 'Phase I/II' study mean?

This means it's an early-stage study designed to first check the safety of a new treatment and then see if it has a positive effect in a small group of people.

Hur länge skulle jag vara med i studien?

You would be part of the study for up to five years, involving regular check-ups and monitoring.

Will I still take my regular Wilson's Disease medicine?

The study aims to see if you can gradually reduce or stop your current Wilson's Disease medication after receiving the study treatment.

Hur du får reda på mer

Prata alltid med din läkare eller specialist innan du bestämmer dig för att delta i en studie.

Diskussion

Gemenskapsdiskussion

Drivs av vårt forum på community.patient.info. Var vänlig och respektfull — detta är inte medicinsk rådgivning.